OCE’s Project 5 in 5 seeks to inspire pragmatic innovation

FDA grants Replimune’s RP1 an accelerated approval on third submission after 10:3 vote from advisory committee
Amid political outcry, advisors accept weak data and give sponsor a chance to complete phase III trial

FDA has granted an accelerated approval to RP1 (vusolimogene oderparepvec) following the agency’s Cellular, Tissue, and Gene Therapies Advisory Committee’s 10:3 vote in support of the biologic in combination with nivolumab for the treatment of advanced melanoma in patients who have progressed on prior anti-PD-1 therapy.

August 07, 2026

Vol.52 No.31

By Jacquelyn Cobb and Paul Goldberg

Drugs & Targets

FDA approves Pluvicto for mHSPC

FDA approved Pluvicto (lutetium Lu 177 vipivotide tetraxetan) in combination with an androgen receptor pathway inhibitor for patients with prostate-specific membrane antigen-positive metastatic androgen pathway modulation-naive/sensitive prostate cancer, commonly known as metastatic hormone-sensitive prostate cancer.

August 07, 2026

Vol.52 No.31

Podcast

Pour a Scotch, we’re talking clinical trials and prediction markets

In last week’s issue of The Cancer Letter, the cover story featured coverage of Kalshi, an online prediction market exchange, launching a pilot program in which one can place bets on both outcomes of trials and FDA decisions.

August 05, 2026

Cancer Policy

FDA’s OCE publishes three final guidances to increase clinical trial enrollment

FDA’s Oncology Center of Excellence has published three final guidance documents intended to broaden eligibility criteria for participation in clinical trials of oncology drugs.

After two CRLs, FDA advisory committee votes in favor of Replimune’s melanoma drug

FDA’s Cellular, Tissue, and Gene Therapies Advisory Committee voted 10:3 in favor of Replimune’s Biologics License Application for RP1 (vusolimogene oderparepvec) in combination with nivolumab for the treatment of advanced melanoma.

July 31, 2026

Vol.52 No.30

Podcast

Hegseth offers soldiers testosterone and FDA loosens safety warnings. Is the science there?

Last week, the Pentagon posted a video on X announcing they will be mandating testosterone screening for troops in the military aged 30 and above. If they test low, they will be offered voluntary testosterone replacement therapy.

July 29, 2026

OCE’s Project 5 in 5 seeks to inspire pragmatic innovation

YOU MAY BE INTERESTED IN

FDA grants Replimune’s RP1 an accelerated approval on third submission after 10:3 vote from advisory committee
Amid political outcry, advisors accept weak data and give sponsor a chance to complete phase III trial

FDA approves Pluvicto for mHSPC

Pour a Scotch, we’re talking clinical trials and prediction markets

FDA’s OCE publishes three final guidances to increase clinical trial enrollment

After two CRLs, FDA advisory committee votes in favor of Replimune’s melanoma drug

Hegseth offers soldiers testosterone and FDA loosens safety warnings. Is the science there?

Renew today!

Subscriber content

Never miss an issue!

Login

OCE’s Project 5 in 5 seeks to inspire pragmatic innovation

YOU MAY BE INTERESTED IN

FDA grants Replimune’s RP1 an accelerated approval on third submission after 10:3 vote from advisory committeeAmid political outcry, advisors accept weak data and give sponsor a chance to complete phase III trial

FDA approves Pluvicto for mHSPC

Pour a Scotch, we’re talking clinical trials and prediction markets

FDA’s OCE publishes three final guidances to increase clinical trial enrollment

After two CRLs, FDA advisory committee votes in favor of Replimune’s melanoma drug

Hegseth offers soldiers testosterone and FDA loosens safety warnings. Is the science there?

Never miss an issue!

Login

FDA grants Replimune’s RP1 an accelerated approval on third submission after 10:3 vote from advisory committee
Amid political outcry, advisors accept weak data and give sponsor a chance to complete phase III trial